LTR Financial Statements From 2010 to 2026

Stocks . Australia . 
Stock . LTR Pharma
LTP Stock   0.49  0.02  3.92%   
Analyzing historical trends in various income statement and balance sheet accounts from LTR Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting LTR Pharma's valuation are summarized below:
Gross Profit
-1.3 M
Market Capitalization
89 M
Enterprise Value Revenue
417.5672
Revenue
1.5 M
Earnings Share
(0.03)
There are currently fourty fundamental ratios for LTR Pharma that can be evaluated and compared over time across peers in the industry. All traders should check LTR Pharma's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

LTR Pharma Total Revenue

2.54 Million

Check LTR Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LTR Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 98.8 K or Interest Expense of 361, as well as many indicators such as . LTR financial statements analysis is a perfect complement when working with LTR Pharma Valuation or Volatility modules.
  
This module can also supplement various LTR Pharma Technical models . Check out the analysis of LTR Pharma Correlation against competitors.

LTR Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets38.9 M37 M7.1 M
Slightly volatile
Other Current Liabilities224.8 K214.1 K115.5 K
Slightly volatile
Total Current Liabilities459.8 K805.7 K470 K
Pretty Stable
Net Debt170.7 K192 K209.6 K
Slightly volatile
Accounts Payable198.2 K278.8 K85.3 K
Slightly volatile
Cash38.4 M36.6 M6.8 M
Slightly volatile
Non Current Assets Total1.4 K1.5 K214.1 K
Slightly volatile
Non Currrent Assets Other216243265
Slightly volatile
Common Stock Shares Outstanding162.5 M208.1 M147.3 M
Slightly volatile
Total Liabilities459.8 K805.7 K470 K
Pretty Stable
Net Invested Capital3.4 M3.4 M1.5 M
Slightly volatile
Short and Long Term Debt287.6 K323.6 K353.2 K
Slightly volatile
Total Current Assets38.7 M36.9 M6.8 M
Slightly volatile
Cash And Short Term Investments38.4 M36.6 M7.9 M
Slightly volatile
Liabilities And Stockholders Equity38.9 M37 M8.3 M
Slightly volatile
Other Current Assets59.5 K74.5 K49.9 K
Slightly volatile
Capital Stock8.9 M12.4 M5.1 M
Slightly volatile
Common Stock53.3 M50.7 M11.6 M
Slightly volatile
Property Plant And Equipment Net1.3 K1.5 K1.6 K
Slightly volatile
Property Plant And Equipment Gross1.3 K1.5 K1.6 K
Slightly volatile
Property Plant Equipment7.9 K14.5 K3.4 K
Slightly volatile
Net Receivables3.5 K4 K4.3 K
Slightly volatile
Inventory15.7 K17.7 K19.3 K
Slightly volatile
Other Stockholder Equity66.3 K74.6 K81.5 K
Slightly volatile

LTR Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income98.8 K94.1 K18.8 K
Slightly volatile
Interest Expense3613806.2 K
Slightly volatile
Selling General Administrative5.4 M5.2 M1.6 M
Slightly volatile
Total Revenue2.5 M2.4 M425 K
Slightly volatile
Research Development4.2 M4 M1.2 M
Slightly volatile
Total Operating Expenses5.6 M8.4 M2.7 M
Slightly volatile

LTR Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Issuance Of Capital Stock8.5 M8.1 M2.1 M
Slightly volatile
Total Cash From Financing Activities7.8 M7.5 M2 M
Slightly volatile
End Period Cash Flow1.9 M3.6 M995.1 K
Slightly volatile
Sale Purchase Of Stock8.5 M8.1 M3.5 M
Slightly volatile
Begin Period Cash Flow1.4 M2 M617.8 K
Slightly volatile

LTR Fundamental Market Drivers

About LTR Pharma Financial Statements

LTR Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although LTR Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in LTR Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on LTR Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue2.4 M2.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for LTR Stock Analysis

When running LTR Pharma's price analysis, check to measure LTR Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LTR Pharma is operating at the current time. Most of LTR Pharma's value examination focuses on studying past and present price action to predict the probability of LTR Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LTR Pharma's price. Additionally, you may evaluate how the addition of LTR Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY